Moleculin Biotech is trading at $0.77, up +7.97%, after encouraging interim Phase 3 Annamycin data highlighted higher remission rates in relapsed or refractory AML without observed cardiotoxicity.
- The update was presented through the H.C. Wainwright conference on September 11, 2026.
- On September 14, 2026, the company announced upcoming Annamycin presentations at AACR and two European scientific meetings.
- The clinical catalyst outweighed broader market weakness as major U.S. indexes declined during the September 14 session.